Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888–897

In Fig. 2 of the article cited above, due to a typographical error, the hazard ratio (HR) of the key secondary composite kidney outcome in the insulin at baseline subgroup was incorrectly reported as 0.74 (95% CI 0.59–0.94) instead of the correct HR of 0.77 (95% CI 0.62–0.94). In addition, the HRs of the secondary composite cardiovascular outcome were incorrectly reported as 0.88 (95% CI 0.71–1.09) for no insulin at baseline and 0.83 (95% CI 0.69–1.01) for insulin at baseline (P for interaction 0.70). The correct HRs for the secondary composite cardiovascular outcome are 0.95 (95% CI 0.74–1.23) for no insulin at baseline and 0.82 (95% CI 0.69–0.97) for insulin at baseline (P for interaction 0.33).